Accessibility Tools
Invert colors
Monochrome
Dark contrast
Light contrast
Low saturation
High saturation
Highlight links
Highlight headings
Screen reader
Read mode
Content scaling
100
%
Font size
100
%
Line height
100
%
Letter spacing
100
%
(678) 384-7220
info@geovax.com
About Us
Company
Leadership
Board of Directors & Corporate Advisors
Scientific Advisory Board
Collaborators
Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Clinical Trials
Investors
Corporate Profile
Press Releases
Media
Events & Presentations
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
Careers
Contact
SEC Filings
SEC Filings
Year
2020
Date
07-07
Description
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
SEC Form
DEFA 14
Download Word
Download Excel
Download PDF
DEFA_14A_-_Schedule_14A_Supplemental_Information_-_Shareholder_Letter.pdf
id
About GeoVax
Company
Leadership
Board of Directors & Corporate Advisors
Scientific Advisory Board
Collaborators
Our Technology
Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Product Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Investors
Corporate Profile
News
Events & Presentations
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
SUBSCRIBE FOR UPDATES FROM GEOVAX
Register to receive email alerts for GeoVax press releases
SUBMIT
Email
About Us
Company
Leadership
Board of Directors & Corporate Advisors
Scientific Advisory Board
Collaborators
Technology
MVA Technology Overview
Gedeptin® Technology Overview
Publications
Pipeline
Pipeline Summary
Oncology
Infectious Diseases
Clinical Trials
Investors
Corporate Profile
Press Releases
Media
Events & Presentations
SEC Filings
GeoVax Stock Information
Corporate Governance
Analyst Coverage
Investor FAQ's
Careers
Contact
Search
